

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)



(10) International Publication Number
WO 2024/193634 A1

(51) International Patent Classification:

C12N 15/85 (2006.01) A61K 48/00 (2006.01)
C07K 14/725 (2006.01) C12N 15/67 (2006.01)
C12N 15/11 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2024/082941

(22) International Filing Date:

21 March 2024 (21.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/082833
21 March 2023 (21.03.2023) CN
PCT/CN2023/099386
09 June 2023 (09.06.2023) CN

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **RIBOX THERAPEUTICS HK LIMITED**

[CN/CN]; Unit 417, 4/F Lippo Ctr Tower Two No. 89
Queensway Admiralty, Hong Kong (CN).

(72) Inventors: **LI, Siqi**; No. 15, Lane 388, Shengrong Road,

Pudong New Area, Shanghai 201315 (CN). **LEI, Yunni**;
No. 15, Lane 388, Shengrong Road, Pudong New Area,
Shanghai 201315 (CN). **SHI, Xiaoliang**; No. 15, Lane
388, Shengrong Road, Pudong New Area, Shanghai 201315
(CN). **ZHANG, Weiyi**; No. 15, Lane 388, Shengrong Road,
Pudong New Area, Shanghai 201315 (CN).

(74) Agent: **NTD UNIVATION INTELLECTUAL PROP-**

ERTY AGENCY LTD.; 10th Floor, Tower C, Beijing
Global Trade Center, 36 North Third Ring Road East,
Dongcheng District, Beijing 100013 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: CIRCULAR RNA AND PREPARATION METHOD THEREOF

(57) Abstract: Provided is an engineered circular RNA molecule which is prepared from a circular RNA precursor comprising a) a 3' self-splicing intron fragment and b) a 5' self-splicing intron fragment, a pharmaceutical composition comprising the circular RNA molecule, and use thereof. Also provided is a vector as well as the method used for preparing the same.



WO 2024/193634 A1